Skip To Main Content
This website is intended exclusively for healthcare professionals residing and/or working in the UAE.
Campus
Campus

Metabolic Risk Factors and Effect of Alirocumab on CV Events

Accumulation of metabolic risk factors substantially increased risk for Mace in patients with recent ACS. Alirocumab treatment reduced Mace consistently, although absolute risk reduction was more pronounced in patients with multiple metabolic risk factors, including patients without diabetes (Ostadal P, et al. [Lancet Diabetes Endocrinol. 2022]).

Related articles
Prospective evaluation of lipid management following ACS in Saudi Arabia (ACOSYM Study)
  • Dyslipidemia
  • Dyslipidemia

Prospective evaluation of lipid management following ACS in Saudi Arabia (ACOSYM Study)

Read article
Statin/ezetimibe SPC for better adherence to LLT
  • Dyslipidemia
  • Cardiovascular
  • Dyslipidemia

Statin/ezetimibe SPC for better adherence to LLT

Read article
Managing Recurrent ASCVD risk of your ACS Patient: A call to Action – GULF Perspective: Part 2
  • Dyslipidemia
  • Cardiovascular
  • Dyslipidemia

Managing Recurrent ASCVD risk of your ACS Patient: A call to Action – GULF Perspective: Part 2

Read article
MAT-KW-2200328/V1/DEC2022